Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  George, Jeffy ^a   Valiant, William G ^a   Mattapallil, Mary J ^b   Walker, Michelle ^c   Huang, Yan Jang S ^d   Vanlandingham, Dana L ^d   Misamore, John ^c   Greenhouse, Jack ^c   Weiss, Deborah E ^c   Verthelyi, Daniela ^e   Higgs, Stephen ^d   Andersen, Hanne ^c   Lewis, Mark G ^c   Mattapallil, Joseph J ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c BIOQUAL INC   (United States)

^d KANSAS STATE UNIVERSITY   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CYTOKINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL; ANTIBODY DEPENDENT ENHANCEMENT; BIOLOGY; CLASSIFICATION; CROSS REACTION; DENGUE; DENGUE VIRUS; IMMUNOLOGY; METABOLISM; MIXED INFECTION; MONKEY DISEASE; PHYSIOLOGY; PROCEDURES; RHESUS MONKEY; SERODIAGNOSIS; VETERINARY MEDICINE; VIREMIA; VIROLOGY; VIRUS LOAD; ZIKA FEVER; ZIKA VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; COINFECTION; COMPUTATIONAL BIOLOGY; CROSS REACTIONS; CYTOKINES; DENGUE; DENGUE VIRUS; INFLAMMATION MEDIATORS; MACACA MULATTA; MONKEY DISEASES; NEUTRALIZATION TESTS; VIRAL LOAD; VIREMIA; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85036562921     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-10901-1     Document Type: Article

References (40)

1. Musso, D. & Gubler, D. J. Zika Virus. Clin Microbiol Rev 29, 487–524, doi:10.1128/CMR.00072-15 (2016).
2. Priyamvada, L. et al. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts. J Virol 90, 5574–5585, doi:10.1128/JVI.03203-15 (2016).
3. Priyamvada, L. et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA 113, 7852–7857, doi:10.1073/pnas.1607931113 (2016).
4. Sirohi, D. et al. The 3.8 A resolution cryo-EM structure of Zika virus. Science 352, 467–470, doi:10.1126/science.aaf5316 (2016).
5. Beltramello, M. et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271–283, doi:10.1016/j.chom.2010.08.007 (2010).
6. Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823–826, doi:10.1126/science.aaf8505 (2016).
7. Kawiecki, A. B. & Christofferson, R. C. Zika Virus-Induced Antibody Response Enhances Dengue Virus Serotype 2 Replication In Vitro. J Infect Dis 214, 1357–1360, doi:10.1093/infdis/jiw377 (2016).
8. Dudley, D. M. et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat Commun 7, 12204, doi:10.1038/ncomms12204 (2016).
9. Osuna, C. E. et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat Med 22, 1448–1455, doi:10.1038/nm.4206 (2016).
10. Halstead, S. B., Shotwell, H. & Casals, J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis 128, 15–22 (1973).
11. Onlamoon, N. et al. Dengue virus-induced hemorrhage in a nonhuman primate model. Blood 115, 1823–1834, doi:10.1182/blood-2009-09-242990 (2010).
12. Chadwick, D., Arch, B., Wilder-Smith, A. & Paton, N. Distinguishing dengue fever from other infections on the basis of simple clinical and laboratory features: application of logistic regression analysis. J Clin Virol 35, 147–153, doi:10.1016/j.jcv.2005.06.002 (2006).
13. Potts, J. A. & Rothman, A. L. Clinical and laboratory features that distinguish dengue from other febrile illnesses in endemic populations. Trop Med Int Health 13, 1328–1340, doi:10.1111/j.1365-3156.2008.02151.x (2008).
14. Simmons, C. P., Farrar, J. J., Nguyen v, V. & Wills, B. Dengue. N Engl J Med 366, 1423–1432, doi:10.1056/NEJMra1110265 (2012).
15. Costa, V. V., Fagundes, C. T., Souza, D. G. & Teixeira, M. M. Inflammatory and innate immune responses in dengue infection: protection versus disease induction. Am J Pathol 182, 1950–1961, doi:10.1016/j.ajpath.2013.02.027 (2013).
16. Murphy, B. R. & Whitehead, S. S. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29, 587–619, doi:10.1146/annurev-immunol-031210-101315 (2011).
17. Rothman, A. L. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11, 532–543, doi:10.1038/nri3014 (2011).
18. Srikiatkhachorn, A. & Green, S. Markers of dengue disease severity. Curr Top Microbiol Immunol 338, 67–82, doi:10.1007/978-3-642-02215-9_6 (2010).
19. Hickey, A. C. et al. Serotype-specific host responses in rhesus macaques after primary dengue challenge. Am J Trop Med Hyg 89, 1043–1057, doi:10.4269/ajtmh.13-0145 (2013).
20. Halstead, S. B. & Palumbo, N. E. Studies on the immunization of monkeys against dengue. II. Protection following inoculation of combinations of viruses. Am J Trop Med Hyg 22, 375–381 (1973).
21. Halstead, S. B., Shotwell, H. & Casals, J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis 128, 7–14 (1973).
22. Rodhain, F. The role of monkeys in the biology of dengue and yellow fever. Comp Immunol Microbiol Infect Dis 14, 9–19 (1991).
23. Halstead, S. B. & O’Rourke, E. J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146, 201–217 (1977).
24. Jessie, K., Fong, M. Y., Devi, S., Lam, S. K. & Wong, K. T. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 189, 1411–1418, doi:10.1086/383043 (2004).
25. Halstead, S. B. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 11(Suppl 4), S830–839 (1989).
26. Passlick, B., Flieger, D. & Ziegler-Heitbrock, H. W. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 74, 2527–2534 (1989).
27. Azeredo, E. L. et al. Differential regulation of toll-like receptor-2, toll-like receptor-4, CD16 and human leucocyte antigen-DR on peripheral blood monocytes during mild and severe dengue fever. Immunology 130, 202–216, doi:10.1111/j.1365-2567.2009.03224.x (2010).
28. Kwissa, M. et al. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe 16, 115–127, doi:10.1016/j.chom.2014.06.001 (2014).
29. Carvalho, D. M. et al. Elevated dengue virus nonstructural protein 1 serum levels and altered toll-like receptor 4 expression, nitric oxide, and tumor necrosis factor alpha production in dengue hemorrhagic Fever patients. J Trop Med 2014, 901276, doi:10.1155/2014/901276 (2014).
30. Modhiran, N. et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med 7, 304ra142, doi:10.1126/scitranslmed.aaa3863 (2015).
31. Belge, K. U. et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 168, 3536–3542 (2002).
32. Halstead, S. B. Pathogenesis of dengue: challenges to molecular biology. Science 239, 476–481 (1988).
33. Lanciotti, R. S. et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 14, 1232–1239, doi:10.3201/eid1408.080287 (2008).
34. Collins, M. H. et al. Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection. Emerging Infectious Diseases 23, 773–781, doi:10.3201/eid2305.161630 (2017).
35. Smith, K. M. et al. Testing of novel dengue virus 2 vaccines in African green monkeys: safety, immunogenicity, and efficacy. Am J Trop Med Hyg 87, 743–753, doi:10.4269/ajtmh.2012.12-0004 (2012).
36. Chiofalo, M. S., Teti, G., Goust, J. M., Trifiletti, R. & La Via, M. F. Subclass specificity of the Fc receptor for human IgG on K562. Cell Immunol 114, 272–281, doi:10.1016/0008-8749(88)90321-8 (1988).
37. Klein, E. et al. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 18, 421–431 (1976).
38. Mattia, K. et al. Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One 6, e27252, doi:10.1371/journal.pone.0027252 (2011).
39. Clark, K. B., Onlamoon, N., Hsiao, H. M., Perng, G. C. & Villinger, F. Can non-human primates serve as models for investigating dengue disease pathogenesis? Front Microbiol 4, 305, doi:10.3389/fmicb.2013.00305 (2013).
40. Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129–1132, doi:10.1126/science.aah6157 (2016).